New Blood-Based Biomarkers Show Promise for Alzheimer's Diagnosis and Monitoring

Researchers are making significant advances in developing blood-based biomarkers for Alzheimer's disease, with new studies revealing promising diagnostic tools and mechanistic insights. A study presented at the 2025 Alzheimer's Association International Conference in Toronto demonstrated that the SPEAR UltraDetect™ pTau 217 assay outperformed other assays in distinguishing amyloid-positive from amyloid-negative individuals, achieving an AUC of 0.95 in a memory clinic cohort and requiring over 100-fold less plasma than competing tests. Meanwhile, separate research has identified interferon gamma (IFN-γ) as a powerful blood-based signal of Alzheimer's disease and a potential mechanistic bridge between genetic risk and damaging microglial inflammation in the brain.

The SPEAR assay showed remarkable robustness even with samples that had been freeze-thawed multiple times, maintaining performance with a mean CV of 5.2% after four to five freeze-thaw cycles. In the memory clinic sample of 119 patients, the assay produced a 4.7-fold difference between amyloid-positive and amyloid-negative groups, compared to a 3.0-fold difference for the Simoa® ALZpath assay. The SPEAR assay also demonstrated 93% agreement with amyloid PET imaging, despite many plasma samples being collected years before the PET scans.

In a community-based cohort from the Human Connectome Project, where most participants were cognitively normal, the SPEAR assay again outperformed the Lumipulse® pTau 217 assay with an AUC of 0.90 compared to 0.82. The assay requires only 1 µL of diluted plasma and maintains higher accuracy even after six freeze-thaw cycles.

The field of Alzheimer's disease research has evolved significantly, shifting from a sole reliance on clinical diagnosis to an integrated approach based on biological markers that reveal the earliest pathological changes. This paradigm shift underscores the importance of biomarkers not only for characterizing disease onset and progression, but also for guiding clinical trials and therapeutic strategies.

The study investigating IFN-γ involved 141 participants, including 71 people with Alzheimer's disease, 44 with mild cognitive impairment, and 28 healthy controls. Alzheimer's patients were older, had less formal education, and were more likely to carry the APOE ϵ4 genotype, which is the most significant genetic risk factor for late-onset Alzheimer's disease. The research examined the relationships between key biomarkers, cognitive performance, and APOE genotypes, developing a predictive model for Alzheimer's disease using a combination of blood markers, clinical information, and APOE genotype.

Current challenges in the field include the validation and standardization of biomarkers across diverse populations, ensuring accessibility, and understanding their relationship to the complex underlying mechanisms of Alzheimer's disease. While various types of biomarkers—ranging from amyloid and tau pathologies to neuroinflammation, synaptic loss, and vascular contributions—have shown promise in early detection, there is an ongoing need to address knowledge gaps and discrepancies in biomarker performance due to genetic, demographic, and methodological differences.

Blood-based biomarkers such as pTau 217 are changing Alzheimer's research, though measuring them reliably across different cohorts remains challenging. Many accessible tests require substantial amounts of plasma, and their performance can suffer when working with archived samples that have been freeze-thawed several times. These constraints are especially important in research that relies on biobanked samples accumulated over decades.

Although early diagnosis of Alzheimer's disease is crucial for effective care, current diagnostic methods often fall short. Physicians usually diagnose Alzheimer's using cognitive tests and advanced imaging, but these approaches can be expensive, inaccessible, or subjective, particularly in less-resourced communities. Tests for biomarkers in cerebrospinal fluid and blood, such as amyloid-β and phosphorylated Tau, remain largely restricted to research settings due to their complexity and cost, highlighting the urgency of identifying simple, reliable, and accessible biomarkers for Alzheimer's diagnosis.